TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28077162
Drug: Standard pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain treatment (oral immediate-release morphine) plus nitrous oxide/oxygen mixture
Study: 28077162
Drug: Standard pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain treatment (oral immediate-release morphine) plus oxygen
Study: 23718718
Drug: Varenicline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline plus nicotine patch (15 mg/16 hour)
Study: 23718718
Drug: Varenicline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline plus placebo patch
Study: 23718718
Drug: Varenicline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline plus nicotine patch
Study: 7930412
Drug: Valproate treatment
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate treatment
Study: 18955565
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) followed by autologous purged stem cell transplantation (ASCT)
Study: 11915269
Drug: Wheelchair biking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheelchair biking therapy for 2 weeks
Study: 356707
Drug: Diazepam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.2 mg/kg)
Study: 7982137
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Vecuronium 0.1 mg/kg without diazepam)
Study: 807170
Drug: Parenteral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral fat free nutrition (primary caloric source glucose)
Study: 30228338
Drug: Sequential seeding
Normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential seeding
Study: 23201472
Drug: GM+G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM+G-CSF
Study: 16555172
Drug: Non-pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological treatment (NPT)
Study: 26272687
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (200 μg)
Study: 25170230
Drug: Furazolidone-based triple
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone-based triple therapy (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 7 days
Study: 25170230
Drug: Furazolidone-based quadruple
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone-based quadruple therapy (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 7 days
Study: 25170230
Drug: Furazolidone-based triple
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone-based triple therapy (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 10 days
Study: 25170230
Drug: Furazolidone-based quadruple
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone-based quadruple therapy (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 10 days
Study: 23176379
Drug: Allicor (time-released
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allicor (time-released garlic-based drug)
Study: 20581879
Drug: Late mRNA-based
Normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late mRNA-based (NucliSens CMV pp67) anti-HCMV treatment
Study: 20581879
Drug: PCR-based preemptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCR-based preemptive HCMV-directed antiviral therapy
Study: 20581879
Drug: Both late
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both late mRNA-based and PCR-based therapies
Study: 18463998
Drug: Psychosocial treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatments (four types) for cocaine dependence
Study: 18463998
Drug: Non-protocol services
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-protocol services (additional treatment services)
Study: 10731499
Drug: Strontium with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strontium with 35 g lactose (load B)
Study: 10731499
Drug: Strontium with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strontium with 17.5 g glucose and 17.5 g galactose (load C)
Study: 8941092
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin infusion (250 IU primed, 600 IU/h continuous)
Study: 8941092
Drug: Heparin/insulin period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin/insulin period
Study: 2060541
Drug: Glipizide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 0.5 mg
Study: 2060541
Drug: Glipizide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 1.0 mg
Study: 2060541
Drug: Glipizide 2.5
Normalized name: glipizide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 2.5 mg
Study: 29577536
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump therapy (control)
Study: 23924302
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention including universal nutritional screening, oral nutritional supplements, red trays, and additional feeding support
Study: 16137945
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 1,200-1,500 mg/day (WHO, North America, Europe)
Study: 16137945
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 800 mg/day (Japan)
Study: 8725991
Drug: Risperidone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (6 mg)
Study: 12900301
Drug: Risperidone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (6 mg) with enhanced community-based skills training
Study: 12900301
Drug: Haloperidol (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (low dose)
Study: 10469192
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days
Study: 10469192
Drug: Pantoprazole, 40
Normalized name: Pantoprazole, 40 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40
Study: 10469192
Drug: Pantoprazole, 40
Normalized name: Pantoprazole, 40 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40
Study: 6366560
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment only (Control)
Study: 30860603
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) alcohol to a target breath alcohol concentration (BrAC) of 0.06 g/dl
Study: 19200175
Drug: APL 200
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL 200 mg bid
Study: 19200175
Drug: APL 400
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL 400 mg bid
Study: 19200175
Drug: APL 800
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL 800 mg qd
Study: 9037327
Drug: Mibefradil 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 50, 100, and 150 mg
Study: 9037327
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30, 60, and 90 mg
Study: 9037327
Drug: Mibefradil 150
Normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mibefradil 150 mg alone or combined with lisinopril 20 mg
Study: 2883695
Drug: Lorazepam (0.057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.057 mg/kg)
Study: 2883695
Drug: Alprazolam (0.029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.029 mg/kg)
Study: 2883695
Drug: Diazepam (0.286
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.286 mg/kg)
Study: 2883695
Drug: Placebo (0.000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.000 mg/kg)
Study: 2883695
Drug: Lorazepam (0.028
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.028 mg/kg)
Study: 2883695
Drug: Alprazolam (0.014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.014 mg/kg)
Study: 2883695
Drug: Diazepam (0.143
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.143 mg/kg)
Study: 24911577
Drug: Lorediplon 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorediplon 5 mg
Study: 24911577
Drug: Lorediplon 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorediplon 10 mg
Study: 24911577
Drug: Lorediplon 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorediplon 1 mg
Study: 22350925
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg (active control)
Study: 22419350
Drug: POIO (preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: POIO (preoperative and intraoperative dose)
Study: 22419350
Drug: POIOPO (preoperative,
Approvals — FDA: no, EMA: no, PMDA: no
Description: POIOPO (preoperative, intraoperative, and postoperative doses)
Study: 22419350
Drug: IO (intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO (intraoperative dose only)
Study: 22419350
Drug: IOPO (intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOPO (intraoperative and postoperative doses)
Study: 20804368
Drug: Cs-4 (Cordyceps
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cs-4 (Cordyceps sinensis) 333 mg, taken 3 times a day for 12 weeks
Study: 18000183
Drug: Coccinia cordifolia
Normalized name: Coccinia grandis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coccinia cordifolia extract (1 g alcoholic extract for 90 days)
Study: 15930077
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy plus olanzapine (mean dose 8.83 mg/day)
Study: 15930077
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy plus placebo
Study: 10584567
Drug: MPA 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA 1,200 mg
Study: 10584567
Drug: MPA 600
Normalized name: MPA
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA 600 mg
Study: 6863091
Drug: Caffeine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (500 mg) administered orally
Study: 29020589
Drug: ChAd3‐EBO‐Z vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd3‐EBO‐Z vaccine
Study: 29020589
Drug: rVSV∆G‐ZEBOV‐GP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSV∆G‐ZEBOV‐GP vaccine
Study: 23431996
Drug: ATG-Fresenius (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-Fresenius (9 mg/kg body weight)
Study: 17580147
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no induction therapy)
Study: 19584690
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with reduced cyclosporine A (CsA) (trough level 3-8 ng/mL)
Study: 19584690
Drug: MMF (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF (3 g/day) with standard CsA
Study: 12514304
Drug: CLA-mix (8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA-mix (8.0 g daily, 76% pure CLA)
Study: 12514304
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil (placebo, 8.0 g daily)
Study: 8762417
Drug: Zhikang Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhikang Oral Liquid (ZK)
Study: 7751430
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg (B5)
Study: 1676675
Drug: Bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 10 mg (B10)
Study: 1676675
Drug: Bisoprolol 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 20 mg (B20)
Study: 1676675
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg (A100)
Study: 1676675
Drug: Nadolol 40
Normalized name: nadolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 40 mg (N40)
Study: 27007998
Drug: Ambroxol oral
Normalized name: ambroxol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol oral tablets
Study: 27007998
Drug: Ambroxol orally-disintegrating
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol orally-disintegrating tablets
Study: 24035344
Drug: Ketamine 0.41
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.41 mg/kg
Study: 24035344
Drug: Ketamine 0.71
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.71 mg/kg
Study: 17414939
Drug: Pramipexole (0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.375 mg/d to a maximum tolerated dose of ≤4.5 mg/d over a 6-week period)
Study: 15708053
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (100 mg) taken 1 to 2 hours before VCD use
Study: 15708053
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (sildenafil + VCD)
Study: 12218949
Drug: Heparin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (100 IU/kg body weight, subcutaneous for 6 days)
Study: 9593384
Drug: Heparin surface-modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin surface-modified (HSM) intraocular lenses (IOLs)
Study: 2212123
Drug: Intradermal platelet-activating
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal platelet-activating factor (PAF-acether)
Study: 2212123
Drug: Platelet activating
Normalized name: Platelet activating factor
DrugBank: Platelet Activating Factor (DB02261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet activating factor antagonist BN52063
Study: 81986
Drug: Control tablet
Normalized name: Daily-Vite Weight Control Tablet
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control tablet substituted
Study: 28526014
Drug: Antihyperglycaemia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihyperglycaemia therapy
Study: 16981050
Drug: Rheumazin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheumazin (10 mg piroxicam, 1 mg dexamethasone, 35 mg orphenadrine, 2.5 mg cyanocobalamin)
Study: 16981050
Drug: Feldene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feldene (20 mg piroxicam)
Study: 12428781
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for depression (CBT-D)
Study: 28864706
Drug: Standard smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard smoking cessation treatment
Study: 2221287
Drug: Hazelden‐type treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hazelden‐type treatment (N = 74)
Study: 2221287
Drug: Traditional‐type treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional‐type treatment (N = 67)
Study: 349319
Drug: Labetalol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (600 mg twice a day)
Study: 349319
Drug: Prindolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prindolol (15 mg twice a day) plus Hydralazine (50 mg three times a day)
Study: 30028640
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of itraconazole 100 mg
Study: 30028640
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of itraconazole 100 mg
Study: 19602188
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) treatment: three sets of 60 s of vibration (30 Hz, +/-4 mm) while standing in a semi-squat position
Study: 19602188
Drug: Control treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment: static squat
Study: 2197898
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg induction and 0.15 mg/kg per min maintenance with N2O/O2
Study: 2197898
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg induction and enfluran maintenance with N2O/O2
Study: 921082
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients
Study: 921082
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to controls
Study: 921082
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients at the time of chemotherapy
Study: 921082
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients between chemotherapy courses
Study: 31331617
Drug: LSD 6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 6.5 μg
Study: 31331617
Drug: LSD 13
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 13 μg
Study: 31331617
Drug: LSD 26
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 26 μg
Study: 31331617
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 μg)
Study: 23855816
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet
Study: 15220947
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB 30 g/day
Study: 15220947
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB 60 g/day
Study: 15220947
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB 80 g/day
Study: 15220947
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB 10 g/day
Study: 15220947
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB 15 g/day
Study: 15220947
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB (all doses)
Study: 15220947
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB (up to 45 g/day)
Study: 11898516
Drug: Various tic-suppressing
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various tic-suppressing treatments including hydrotherapy, behavioral treatments, pharmacotherapy, botulinum toxin, immunomodulatory therapy, and surgery; specific dosages and durations not available.
Study: 9850434
Drug: Patented soft
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patented soft gelatine capsule with 80 mg of silybin in a 1:2 complex with phosphatidylcholine
Study: 9850434
Drug: Hard shell
Normalized name: Hard Gelatin Capsule Shell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard shell capsule with 80 mg of silybin in a 1:2 complex with phosphatidylcholine
Study: 8115666
Drug: Piroxicam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (40 mg, intramuscular injection)
Study: 8115666
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (500 mg, intravenous injection)
Study: 8115666
Drug: Naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2 mg, intravenous injection)
Study: 19650782
Drug: Levothyroxine (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (64 nmol) and Liothyronine (16 nmol) supplement
Study: 19816018
Drug: Neuroaid (MLC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroaid (MLC 601), 4 capsules 3 times a day for 4 weeks
Study: 19816018
Drug: Placebo, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 4 capsules 3 times a day for 4 weeks
Study: 16621658
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist (DA) monotherapy
Study: 15599534
Drug: CO2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CO2 therapy after liposuction (2 weekly applications for 10 weeks)
Study: 15599534
Drug: CO2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CO2 therapy alone (2 weekly applications for 10 weeks)
Study: 9483214
Drug: L‐myc oncoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐myc oncoprotein
Study: 10562823
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg base/kg body weight over 3 days)
Study: 8311568
Drug: Amodiaquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (25 mg base/kg body weight over 3 days)
Study: 8311568
Drug: Quinine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (8 mg/kg every 8 h for 3 or 5 days)
Study: 8311568
Drug: Sulphadoxine-pyrimethamine (25-1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadoxine-pyrimethamine (25-1.25 mg/kg, in one dose)
Study: 29521887
Drug: Team-Based Learning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Team-Based Learning (TBL), 6 hours (2 hours weekly for 3 weeks)
Study: 29521887
Drug: Lecture-style classes,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecture-style classes, 6 hours (2 hours weekly for 3 weeks)
Study: 24676848
Drug: Low-magnitude high-frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-magnitude high-frequency vibration (LMHFV) - 20 min daily, 35 Hz, 0.3 g, 5 days/week for 18 months